Geneva, April 27 -- International Clinical Trials Registry received information related to the study (NCT07529535) titled 'A First-in-Human Study of ALK-N001 for Injection in Patients With Advanced Solid Tumors' on April 8.
Study Type: Interventional
Study Design:
Allocation: Non-Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).
Primary Sponsor: Zhejiang Anglikang Pharmaceutical Co., Ltd.
Condition:
Advance Solid Tumors
Intervention:
Drug: ALK-N001 for Injection
Recruitment Status: Not recruiting
Phase: Phase 1
Date of First Enrollment: June 5, 2025
Target Sample Size: 16
Countries of Recruitment:
China
To know more, visit https://clinicaltrials.gov/study/NCT0752...